🤖Remedy Robotics Raises $62M Series B to Robotically Treat Stroke Patients
Robot surgeons for stroke care just got $62M in funding
TL;DR
Remedy Robotics raised $62 million in Series B funding led by DCVC to push its N1 System toward FDA approval for neurovascular procedures. The robot already runs remote stroke-related procedures and works with over 100 hospitals. For anyone building medical robotics or tele-health tooling, this is a serious signal that autonomy in interventional procedures is getting real money.
Remedy Robotics just raised $62 million in Series B funding, and the money is aimed at getting its N1 System through clinical trials and toward FDA approval for neurovascular intervention. The round was led by DCVC, with UC Investments, Skip Capital, and Hostplus joining, plus existing backers Build Collective, Blackbird, Divergent Capital, and KdT Ventures. If you work anywhere near medical imaging, computer vision, or robotics, this one is worth a closer look. The N1 combines robotics, machine learning, and computer vision to read preoperative imaging, simulate procedures, and register images in real time. Remedy is also building toward autonomous endovascular procedures, which is a much harder control problem than teleoperation. The company says it works with more than 100 hospitals and reported completing remote neurointerventional procedures in October 2025. It plans a pivotal trial with the University of California and aims to ship prototypes across its clinical network. The N1 is not approved for sale or clinical use anywhere yet, so treat the timelines as ambitious until the trial data lands.

Key Points
Remedy Robotics closed a $62 million Series B round, with DCVC leading and UC Investments, Skip Capital, and Hostplus joining the new money on the cap table.
Keep reading — it's free
Enter your email to keep reading — plus the best of AI & tech, daily. Free, forever.
Already a member? Sign in
Comments
Be the first to comment